Adverum Biotechnologies, Inc. (ADVM): Price and Financial Metrics


Adverum Biotechnologies, Inc. (ADVM)

Today's Latest Price: $14.21 USD

0.24 (1.72%)

Updated Nov 24 4:00pm

Add ADVM to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 389 in Biotech

See all "A" rated Strong Buy stocks

ADVM Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for ADVM is 0 -- better than merely 8.72% of US stocks.
  • With a price/sales ratio of 3,877.97, Adverum Biotechnologies Inc has a higher such ratio than 99.71% of stocks in our set.
  • As for revenue growth, note that ADVM's revenue has grown -72.31% over the past 12 months; that beats the revenue growth of just 2.25% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Adverum Biotechnologies Inc are RVNC, AUPH, VTVT, VNRX, and GERN.
  • ADVM's SEC filings can be seen here. And to visit Adverum Biotechnologies Inc's official web site, go to www.adverum.com.

ADVM Stock Price Chart Interactive Chart >

Price chart for ADVM

ADVM Price/Volume Stats

Current price $14.21 52-week high $26.98
Prev. close $13.97 52-week low $7.36
Day low $13.96 Volume 811,892
Day high $14.57 Avg. volume 1,329,722
50-day MA $11.85 Dividend yield N/A
200-day MA $14.75 Market Cap 1.39B

Adverum Biotechnologies, Inc. (ADVM) Company Bio


Adverum Biotechnologies, Inc., a gene therapy company, engages in discovering and developing novel medicines that offer therapeutic benefit to patients suffering from chronic or debilitating disease. It primary focuses on developing AVA-101, which is in a Phase IIa trial for the treatment of wet age-related macular degeneration (AMD). The company was founded in 2006 and is based in Menlo Park, California.


ADVM Latest News Stream


Event/Time News Detail
Loading, please wait...

ADVM Latest Social Stream


Loading social stream, please wait...

View Full ADVM Social Stream

Latest ADVM News From Around the Web

Below are the latest news stories about Adverum Biotechnologies Inc that investors may wish to consider to help them evaluate ADVM as an investment opportunity.

Assessing Adverum

Procrastination is my sin. It brings me naught but sorrow. I know that I should stop it. In fact, I will--tomorrow”― Gloria Pitzer Today, we look at a name that made me some significant profits earlier this year. However, the stock has fallen on some hard times, and I have...

Bret Jensen on Seeking Alpha | September 29, 2020

Adverum Bio raises $189M via public offering

Adverum Biotechnologies (ADVM) has priced its public offering of 14.5M common shares at $13.00/share, for expected gross proceeds of ~$188.5M.Underwriters' overallotment is an additional 2,175,000 shares.Closing date is August 17.Shares are down 6% premarket. See how ADVM has performed against similar stocks.Previously: Adverum readies $200M equity offering (Aug. 11)...

Seeking Alpha | August 13, 2020

Adverum Biotechnologies Announces Pricing of Public Offering of Common Stock

REDWOOD CITY, Calif., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting…

GlobeNewswire | August 12, 2020

Adverum Biotechnologies Announces Positive Interim Data from Cohorts 1-4 from OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for wet AMD, Reports Recent Business Progress and Second Quarter 2020 Financial Results

-- Continued robust treatment response from both high and low doses -- -- Long-term durability beyond 15 months from single IVT injection with zero…

GlobeNewswire | August 10, 2020

Adverum Biotechnologies to Host a Conference Call and Webcast to Report Second Quarter 2020 Financial Results and Provide Corporate Update

REDWOOD CITY, Calif., July 29, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting…

GlobeNewswire | July 29, 2020

Read More 'ADVM' Stories Here

ADVM Price Returns

1-mo 14.97%
3-mo 15.43%
6-mo -30.07%
1-year 36.37%
3-year 365.90%
5-year 42.81%
YTD 23.35%
2019 265.71%
2018 -10.00%
2017 20.69%
2016 -69.54%
2015 -82.37%

Continue Researching ADVM

Here are a few links from around the web to help you further your research on Adverum Biotechnologies Inc's stock as an investment opportunity:

Adverum Biotechnologies Inc (ADVM) Stock Price | Nasdaq
Adverum Biotechnologies Inc (ADVM) Stock Quote, History and News - Yahoo Finance
Adverum Biotechnologies Inc (ADVM) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8032 seconds.